This database contains 651 studies, archived under the term: "Cognition"
Click here to filter this large number of results.
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation
Freund, Hans-Joachim,
Kuhn, Jens,
Lenartz, Doris,
Mai, Jürgen K.,
Schnell, Thomas,
Klosterkoetter, Joachim,
Sturm, Volker
Background: Dementia represents one of the most challenging health problems. Despite intense research, available therapies have thus far only achieved modest results. Deep brain stimulation (DBS) is an effective treatment option for some movement disorders and is under study for psychiatric applications. Recently, diencephalic DBS revealed selective effects on memory functions, another facet of subcortical […]
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]
Costs of dementia in Hungary
Érsek, K.,
Kovács, T.,
Wimo, A.,
Kárpati, K.,
Brodszky, V.,
Péntek, M.,
Jönsson, L.,
Gustavsson, A.,
McDaid, D.,
Kenigsberg, P. A.,
Valtonen, H.,
Gulácsi, L.
Objective: The main aim of this paper is to give an overview on the quality of life, health care utilisation and costs of dementia in Hungary.; Method: A cross-sectional non-population based study of 88 consecutive dementia patients and their caregivers was conducted in three GP practices and one outpatient setting in 2008. Resource Utilization in […]
Effects of cognitive training on gray matter volumes in memory clinic patients with subjective memory impairment
Engvig, Andreas,
Fjell, Anders M.,
Westlye, Lars T.,
Skaane, Nina V.,
Dale, Anders M.,
Holland, Dominic,
Due-Tønnessen, Paulina,
Sundseth, Øyvind,
Walhovd, Kristine B.
Subjective memory impairment (SMI) is a common risk factor for Alzheimer’s disease, with few established options for treatment. Here we investigate the effects of two months episodic memory training on regional brain atrophy in 19 memory clinic patients with SMI. We used a sensitive longitudinal magnetic resonance imaging protocol and compared the patients with 42 […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]